Monoclonal antibodies (mAbs) are a rapidly growing class of human therapeutics representing approximately 25% of drugs under development. Human mAbs possess diverse advantages over animal-derived antibodies, thus attracts increasing attention for clinical applications.
Low or even no
immunogenic risk
Better tolerated
& less rapidly cleared
High affinity binding
& functional activities
Although rodent monoclonal antibodies (mAbs) have been long regarded as potential therapeutic agents, a major obstacle for clinical applications has been their immunogenicity in human. The process of "humanization" is thus applied to mAbs whose the protein sequences need to be modified to increase their similarity to antibody variants produced naturally in humans.
Human hybridoma technology preserves the authentic sequence and pairing of antibody DNA from a natural B cell, thus leading to the expression of a naturally occurring full-length human mAb.
TOHU™ human hybridoma is an innovation with super efficiency. It overcomes limitations of low fusion efficiency, reduced binding affinity and low yield in existing hybridoma technologies, thus offering an important tool for development of human monoclonal antibodies.
